Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Molina Healthcare (MOH)

NYSE: MOH · Healthcare Plans · Long Beach, CA

Our rating: Cautious

Cautious reaffirmed at $209.15, moderate conviction, October 23, 2026.

Breaks if: The cautious view is wrong if Molina's free cash flow recovers to a positive figure above $350 million in each of the next two consecutive quarterly filings (Q4 2026 and Q1 2027), demonstrating that the more than $1.1 billion earnings-to-cash gap in the current period was a timing anomaly rather than a structural claims deterioration. On the price side, the call is also wrong if MOH trades above $252 within the next twelve months without any corresponding improvement in the cash picture, which would imply the market has visibility into claim trends or contract wins that the current filings do not yet reflect.

Key figures

Market value$10.4B
Revenue, last 12 months$44.1B
Net income, last 12 months−$48M
Free cash flow, last 12 months$238M
Price to earningsn/a
Free cash flow yield2.3%
Dividend yield0.0%
Operating margin0.4%
Return on equity−1.2%
Beta to the S&P 5000.12
Volatility, annualized51.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$11.1B−3.4%$0.73−$196M
June 30, 2026$10.9B−4.8%$1.19−$324M
March 31, 2026$10.8B−3.1%$0.27$1.1B
December 31, 2025$11.4B8.3%$-2.87−$297M
September 30, 2025$11.5B11.0%$1.51−$163M
June 30, 2025$11.4B15.7%$4.75−$344M
March 31, 2025$11.1B12.2%$5.45$168M
December 31, 2024$10.5B16.0%$4.45−$235M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 56 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.